Investor Relations

Upcoming Event

Evercore ISI HealthCONx Conference

Dec 3 12:30 pm EST – Dec 5, 2019

Latest Financial Results

Q3 2019

Quarter Ended Jun 30, 2019

Latest Annual Filing

Company Overview

NeuBase Therapeutics, Inc. is developing its modular peptide-nucleic acid antisense oligonucleotide (PATrOL™) platform to address genetic diseases caused by mutant proteins with a single, cohesive approach. The systemically-deliverable PATrOL therapies have the potential to improve upon current gene silencing treatments by combining the advantages of synthetic approaches with the precision of antisense technologies. NeuBase intends to use its platform to address repeat expansion disorders, with an initial focus on Huntington’s disease and myotonic dystrophy, as well as a variety of other genetic disorders.

Investor Contact Information

Company

NeuBase Therapeutics, Inc.
700 Technology Drive
Pittsburgh, PA 15219
T: 646-450-1790
info@neubasetherapeutics.com

Investor Relations

LifeSci Advisors, LLC
Dan Ferry
1 International Place
14th Floor
Boston, MA 02110
T: 617-535-7746
daniel@lifesciadvisors.com

Transfer Agent

Standard Registrar and Transfer Company
440 East 400 South
Suite 200
Salt Lake City, UT 84111
T: 801-571-8844